Aurora kinase A inhibitor, LY3295668 erbumine: a phase 1 monotherapy safety study in patients with locally advanced or metastatic solid tumors von Chu, Quincy Siu-chung, Bouganim, Nathaniel, Fortier, Caroline, Zaknoen, Sara, Stille, John R., Kremer, Jill D., Yuen, Eunice, Hui, Yu-Hua, de la Peña, Amparo, Lithio, Andrew, Smith, Patricia S., Batist, Gerald

Volltext

Randomized, double-blind, placebo-controlled, multicenter phase II study of the efficacy and safety of apricoxib in combination with either docetaxel or pemetrexed in patients with... von Edelman, Martin J, Tan, Ming T, Fidler, Mary J, Sanborn, Rachel E, Otterson, Greg, Sequist, Lecia V, Evans, Tracey L, Schneider, Bryan J, Keresztes, Roger, Rogers, John S, de Mayolo, Jorge Antunez, Feliciano, Josephine, Yang, Yang, Medeiros, Michelle, Zaknoen, Sara L

Volltext

Multicenter Phase II Trial of Temozolomide in Patients With Anaplastic Astrocytoma or Anaplastic Oligoastrocytoma at First Relapse von Yung, W.K. Alfred, Prados, Michael D., Yaya-Tur, Ricardo, Rosenfeld, Steven S., Brada, Michael, Friedman, Henry S., Albright, Robert, Olson, Jeffrey, Chang, Susan M., O'Neill, Alison M., Friedman, Allan H., Bruner, Janet, Yue, Nancy, Dugan, Margaret, Zaknoen, Sara, Levin, Victor A.

Volltext

Phase II Trial of Temozolomide in Patients With Progressive Low-Grade Glioma von QUINN, Jennifer A, REARDON, David A, AVGEROPOULOS, Nicholas, FINLAY, Jonathan, TOURT-UHLIG, Sandra, AFFRONTI, Mary Lou, EVANS, Brandon, STAFFORD-FOX, Valerie, ZAKNOEN, Sara, FRIEDMAN, Henry S, FRIEDMAN, Allan H, RICH, Jeremy N, SAMPSON, John H, PROVENZALE, James M, MCLENDON, Roger E, GURURANGAN, Sridharan, BIGNER, Darell D, HERNDON, James E

Volltext

A Phase Ib and Pharmacokinetic Trial of Patupilone Combined with Carboplatin in Patients with Advanced Cancer von FORSTER, Martin, KAYE, Stan, OZA, Amit, SKLENAR, Ivo, JOHRI, Anandhi, CHEUNG, Wing, ZAKNOEN, Sara, GORE, Martin

Volltext

A phase Ib study of oral Chk1 inhibitor LY2880070 as monotherapy in patients with advanced or metastatic cancer von Miller, Wilson H., Chu, Quincy S., Bouganim, Nathaniel, Jonker, Derek J., Batist, Gerald, Buhlaiga, Najwa J, Lheureux, Stephanie, Spratlin, Jennifer L., Alcindor, Thierry, Smith, Patricia S, Owen, Joel, Zaknoen, Sara L., Stille, John R., Fortier, Caroline, Vincett, Darcy, Oza, Amit M.

Volltext

Apricoxib, a Novel Inhibitor of COX-2, Markedly Improves Standard Therapy Response in Molecularly Defined Models of Pancreatic Cancer von KIRANE, Amanda, TOOMBS, Jason E, OSTAPOFF, Katherine, CARBON, Juliet G, ZAKNOEN, Sara, BRAUNFELD, Jordan, SCHWARZ, Roderich E, BURROWS, Francis J, BREKKEN, Rolf A

Volltext

Risks of thromboembolic events among patients diagnosed with metastatic pancreatic ductal adenocarcinoma treated with chemotherapy von Bapat, Bela, Bhurke, Sharvari, Rosen, Edward, Stokes, Michael, Bhagnani, Tarun, Nordstrom, Beth, Zaknoen, Sara, Qadan, Ammar

Volltext

Abstract CT083: A Phase I/II study of aurora kinase A inhibitor, LY3295668 erbumine (AK-01): Safety as monotherapy in patients with locally advanced or metastatic solid tumors von Chu, Quincy, Bouganim, Nathaniel, Fortier, Caroline, Zaknoen, Sara, Stille, John R., Kremer, Jill D., Yuen, Eunice, Hui, Yu-Hua, Peña, Amparo de la, Lithio, Andrew, Smith, Patricia S., Batist, Gerald

Volltext

Abstract CT019: Population pharmacokinetics of an aurora kinase A inhibitor, LY3295668 erbumine (AK-01), in patients with locally advanced or metastatic solid tumors von Yuen, Eunice, Hui, Yu-Hua, Peña, Amparo de la, Tate, Sonya C., Stille, John R., Lithio, Andrew, Smith, Patricia S., Chu, Quincy, Batist, Gerald, Bouganim, Nathaniel, Fortier, Caroline, Zaknoen, Sara, Kremer, Jill

Volltext

A phase Ib study of oral Chk1 inhibitor LY2880070 in combination with gemcitabine in patients with advanced or metastatic cancer von Chu, Quincy S., Jonker, Derek J., Provencher, Diane M., Miller, Wilson H., Bouganim, Nathaniel, Shields, Anthony Frank, Shapiro, Geoffrey, Sawyer, Michael B., Lheureux, Stephanie, Samouelian, Vanessa, Gotlieb, Walter H., Esfahani, Khashayar, Zaknoen, Sara L., Smith, Patricia S, Owen, Joel, Fortier, Caroline, Stille, John R., Vincett, Darcy, Oza, Amit M.

Volltext

Therapeutic potential of ERK5 targeting in triple negative breast cancer von Ortiz-Ruiz, María Jesús, Álvarez-Fernández, Stela, Parrott, Tracy, Zaknoen, Sara, Burrows, Francis J, Ocaña, Alberto, Pandiella, Atanasio, Esparís-Ogando, Azucena

Volltext

A Randomized, Placebo-Controlled, Multicenter, Biomarker-Selected, Phase 2 Study of Apricoxib in Combination with Erlotinib in Patients with Advanced Non–Small-Cell Lung Cancer von Gitlitz, Barbara J., Bernstein, Eric, Santos, Edgardo S., Otterson, Greg A., Milne, Ginger, Syto, Mary, Burrows, Francis, Zaknoen, Sara

Volltext

Potent Antimyeloma Activity of a Novel ERK5/CDK Inhibitor von ALVAREZ-FERNANDEZ, Stela, ORTIZ-RUIZ, María Jesus, PARROTT, Tracy, ZAKNOEN, Sara, OCIO, Enrique M, SAN MIGUEL, Jesús, BURROWS, Francis J, ESPARIS-OGANDO, Azucena, PANDIELLA, Atanasio

Volltext

Epithelial―mesenchymal transition increases tumor sensitivity to COX-2 inhibition by apricoxib von KIRANE, Amanda, TOOMBS, Jason E, LARSEN, Jill E, OSTAPOFF, Katherine T, MESHAW, Kathryn R, ZAKNOEN, Sara, BREKKEN, Rolf A, BURROWS, Francis J

Volltext

Biomarker‐based phase I dose‐escalation, pharmacokinetic, and pharmacodynamic study of oral apricoxib in combination with erlotinib in advanced nonsmall cell lung cancer von Reckamp, Karen, Gitlitz, Barbara, Chen, Lin‐Chi, Patel, Ravi, Milne, Ginger, Syto, Mary, Jezior, Deborah, Zaknoen, Sara

Volltext

Phase II study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in patients with taxane‐refractory/resistant nonsmall cell lung carcinoma von Kim, Edward S., Kies, Merrill S., Fossella, Frank V., Glisson, Bonnie S., Zaknoen, Sara, Statkevich, Paul, Munden, Reginald F., Summey, Carmen, Pisters, Katherine M.W., Papadimitrakopoulou, Vali, Tighiouart, Mourad, Rogatko, Andre, Khuri, Fadlo R.

Volltext

Phase I dose escalation study of TG02 in patients with advanced hematologic malignancies von Roboz, Gail J., Khoury, Hanna Jean, Shammo, Jamile M., Syto, Mary, Burrows, Francis, Zaknoen, Sara L., Jabbour, Elias

Volltext

Apricot-P: A randomized placebo-controlled phase II study of COX-2 inhibitor apricoxib or placebo in combination with gemcitabine and erlotinib in advanced or metastatic adenocarci... von Modiano, Manuel, Keogh, George P., Manges, Robert, Stella, Philip J., Milne, Ginger, Looper, Ella, Zaknoen, Sara L.

Volltext

Abstract 339: Apricoxib, a selective COX-2 inhibitor, suppresses IL-27-mediated STAT3 activation and potentiates its inhibition of epithelial to mesenchymal transition in human non... von Kachroo, Puja, Lee, Mi-Heon, Lee, Gina, Krysan, Kostyantyn, Walser, Tonya C., Sharma, Sherven, Zaknoen, Sara, Dubinett, Steven M., Lee, Jay M.

Volltext